Compare PepsiCo, Inc. (PEP) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PepsiCo, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? PepsiCo, Inc. trades at $127.64 (market cap $174.89B), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.14B). The key difference: PepsiCo, Inc. is far larger — about 81.7× Recursion Pharmaceuticals Inc's market cap, and PepsiCo, Inc. pays a 4.61% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold PepsiCo, Inc. for 107 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| PEP | RXRX | |
|---|---|---|
Market Cap | $174.89B | $2.14B |
Volume | 23,968,864 | 30,789,535 |
Sector | Consumer Staples | Health |
52-Week High | $170.44 | $6.79 |
52-Week Low | $123.64 | $2.84 |
Typical Hold Time | 107 Days | 22 Days |
Enterprise Value | $215.61B | $1.66B |
Dividend Yield | 4.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PepsiCo (PEP) trades at $123.64, down 1.65% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS of $2.34 surpassing the $2.29 expectation. Revenue reached $93.93B in 2025, though net income margin dipped to 8.77%. Recent news highlights price cuts on snacks like Doritos to address consumer pushback on high prices.
The outlook is mixed: strong profitability metrics like a 51.59% ROE and a consensus analyst price target of $146.77 suggest upside potential, but competitive pressures and recent net margin compression pose risks. Institutional activity shows mixed signals with some firms increasing stakes while others reduce holdings.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
